MX379501B - Vector hsv oncolítico. - Google Patents

Vector hsv oncolítico.

Info

Publication number
MX379501B
MX379501B MX2016005488A MX2016005488A MX379501B MX 379501 B MX379501 B MX 379501B MX 2016005488 A MX2016005488 A MX 2016005488A MX 2016005488 A MX2016005488 A MX 2016005488A MX 379501 B MX379501 B MX 379501B
Authority
MX
Mexico
Prior art keywords
hsv
ohsv
present
hsv vector
inventive
Prior art date
Application number
MX2016005488A
Other languages
English (en)
Other versions
MX2016005488A (es
Inventor
Hiroaki Uchida
Iii Joseph C Glorioso
Justus Cohen
Paola Grandi
Original Assignee
Univ Pittsburgh Commonwealth Sys Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh Commonwealth Sys Higher Education filed Critical Univ Pittsburgh Commonwealth Sys Higher Education
Publication of MX2016005488A publication Critical patent/MX2016005488A/es
Publication of MX379501B publication Critical patent/MX379501B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16645—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16661—Methods of inactivation or attenuation
    • C12N2710/16662—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16671—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un Virus oncolítico del Herpes Simple recombinante (oHSV) que comprende un ligante no-HSV específico para una molécula (proteína, lípido, o determinante de carbohidratos) presentes en la superficie de una célula (tal como una célula de cáncer) y una o más copias de una o más secuencias diana de microARN insertadas en uno o más loci de genes HSV, preferiblemente uno o más gen(es) HSV necesario para la replicación de HSV en las células normales (es decir, no cancerosas). La invención proporciona además las acciones y composiciones farmacéuticas que comprenden el oHSV inventivo y métodos para matar las células tumorales que emplean el oHSV inventivo.
MX2016005488A 2013-10-28 2014-10-28 Vector hsv oncolítico. MX379501B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361896497P 2013-10-28 2013-10-28
PCT/US2014/062676 WO2015066042A1 (en) 2013-10-28 2014-10-28 Oncolytic hsv vector

Publications (2)

Publication Number Publication Date
MX2016005488A MX2016005488A (es) 2016-10-03
MX379501B true MX379501B (es) 2025-03-11

Family

ID=53005031

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016005488A MX379501B (es) 2013-10-28 2014-10-28 Vector hsv oncolítico.
MX2021001158A MX2021001158A (es) 2013-10-28 2016-04-27 Vector hsv oncolitico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021001158A MX2021001158A (es) 2013-10-28 2016-04-27 Vector hsv oncolitico.

Country Status (17)

Country Link
US (5) US10201575B2 (es)
EP (3) EP3184641B1 (es)
JP (3) JP6588024B2 (es)
KR (2) KR102490462B1 (es)
CN (2) CN106068326B (es)
AU (1) AU2014342465B2 (es)
BR (1) BR112016009465A8 (es)
CA (1) CA2928956A1 (es)
DK (1) DK3184641T3 (es)
ES (2) ES2781852T3 (es)
IL (2) IL245312B (es)
MX (2) MX379501B (es)
NZ (1) NZ720021A (es)
PT (1) PT3184641T (es)
RU (1) RU2719190C2 (es)
SG (1) SG11201603119RA (es)
WO (1) WO2015066042A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011130749A2 (en) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
JP6588024B2 (ja) 2013-10-28 2019-10-09 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 腫瘍溶解性ｈｓｖベクター
HUE054563T2 (hu) * 2015-02-11 2021-09-28 Univ Bologna Alma Mater Studiorum Újracélzott herpeszvírus glikoprotein-H fúzióval
CA3010987A1 (en) 2016-01-08 2017-07-13 Replimune Limited Oncolytic herpes simplex virus type 1 strain
BR112018015390A2 (pt) 2016-01-27 2018-12-18 Oncorus, Inc. vetores virais oncolíticos e usos dos mesmos
BR112018069075A2 (pt) * 2016-03-19 2019-01-29 F1 Oncology, Inc. métodos e composições para transduzir linfócitos e expansão regulada dos mesmos
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
PL3377637T3 (pl) * 2016-04-08 2020-09-07 Krystal Biotech, Inc. Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry
EP3380621A4 (en) * 2016-04-22 2019-05-08 Immvira Co., Limited CONSTRUCTION OF THE VECTOR OF OBLIGATES ONCOLYTIC HERPES SIMPLEX VIRUSES (OHSV) AND CANCER THERAPY CONSTRUCTIONS
US20190106709A1 (en) * 2016-04-29 2019-04-11 Virogin Biotech Canada Ltd Hsv vectors with enhanced replication in cancer cells
HUE053007T2 (hu) 2016-06-09 2021-06-28 Univ Bologna Alma Mater Studiorum Herpeszvírus módosított D glikoproteinnel
US11007236B2 (en) 2016-06-09 2021-05-18 Alma Mater Studiorum Universita Di Bologna Herpesvirus with modified glycoprotein B
WO2017218689A1 (en) 2016-06-14 2017-12-21 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Expression of nkg2d activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells
WO2018006005A1 (en) 2016-06-30 2018-01-04 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
EP3472318B1 (en) * 2016-07-08 2023-09-06 Exuma Biotech Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
EP4403229A3 (en) * 2016-07-29 2024-08-14 Ohio State Innovation Foundation Expression of pten-long with oncolytic viruses
GB201616365D0 (en) * 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
KR20190128050A (ko) 2017-02-03 2019-11-14 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 종양용해성 바이러스 요법
WO2018161825A1 (zh) * 2017-03-09 2018-09-13 厦门大学 一种重组单纯疱疹病毒及其用途
WO2019023483A1 (en) * 2017-07-26 2019-01-31 Oncorus, Inc. ONCOLYTIC VIRAL VECTORS AND USES THEREOF
WO2019032866A1 (en) * 2017-08-09 2019-02-14 Ohio State Innovation Foundation ONCOLYTIC VIRUS CARRYING E-CADHERIN AND USES THEREOF
GB201714430D0 (en) * 2017-09-07 2017-10-25 Micol Romain Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
JP2021514190A (ja) * 2018-02-19 2021-06-10 コンバインド セラピューティクス インコーポレイテッドＣｏｍｂｉｎｅｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． コード化リボ核酸の器官保護発現および調節のための組成物および方法
WO2019099947A1 (en) * 2017-11-16 2019-05-23 Virogin Biotech Canada Ltd Targeting moiety-decorated oncolytic viruses
US11865081B2 (en) 2017-12-29 2024-01-09 Virogin Biotech Canada Ltd. Oncolytic viral delivery of therapeutic polypeptides
EP3781188A4 (en) 2018-04-13 2022-03-02 2seventy bio, Inc. ADOPTIVE CELL THERAPY
MX2020011257A (es) 2018-04-27 2021-01-15 Krystal Biotech Inc Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
JP2021526387A (ja) * 2018-05-31 2021-10-07 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 抗原的にステルス化された腫瘍溶解性ウイルス
KR101998793B1 (ko) * 2018-09-04 2019-07-10 의료법인 성광의료재단 재조합 단순 헤르페스 바이러스의 제조를 위한 벡터
CN111117973A (zh) * 2018-10-30 2020-05-08 中国科学院武汉病毒研究所 一种受microRNA调控的重组溶瘤肠道病毒71型及应用
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
WO2020252093A1 (en) * 2019-06-10 2020-12-17 Infectious Disease Research Institute Methods and compositions of astrovirus replicons
US20220380735A1 (en) 2019-10-10 2022-12-01 Oncorus, Inc. Dual viruses and dual oncolytic viruses and methods of treatment
CN114761030A (zh) * 2019-11-01 2022-07-15 休斯敦系统大学 具有诱导的抗肿瘤免疫的溶瘤病毒疗法
WO2021246815A1 (ko) * 2020-06-03 2021-12-09 주식회사 젠셀메드 Hvec의 세포외 도메인과 암세포 표적화 영역의 융합 단백질을 발현할 수 있는 발현 카세트를 가지는 재조합 헤르페스 심플렉스 바이러스 및 그 용도
EP4166656A4 (en) * 2020-06-12 2024-08-07 Gencellmed Inc. MULTI-TARGET RECOMBINANT HERPES SIMPLEX VIRUSES AND THEIR USE
JP7235334B2 (ja) * 2020-11-26 2023-03-08 イムヴィラ・カンパニー・リミテッド 癌の治療に用いる腫瘍溶解性単純ヘルペスウイルス（ｏＨＳＶ）偏性ベクター及びその構築体の構築
BR112023020209A2 (pt) 2021-04-02 2023-12-19 Krystal Biotech Inc Genoma do vírus do herpes recombinante, vírus do herpes, composição farmacêutica, uso do vírus do herpes ou da composição farmacêutica, método para expressar, realçar, aumentar, ampliar e/ou suplementar os níveis de um polipeptídeo imunomodulatório, método para prover alívio profilático, paliativo ou terapêutico, e, método para tratar câncer
CN114010666B (zh) * 2021-10-22 2024-05-07 上海交通大学 溶瘤病毒、parp抑制剂及pd-1抗体在制备抗肿瘤药物中的应用
TW202342758A (zh) * 2022-01-29 2023-11-01 加拿大商復諾健生物科技加拿大有限公司 轉錄及轉譯雙重調節之溶瘤單純疱疹病毒載體
WO2024151990A1 (en) * 2023-01-13 2024-07-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Effective oncolytic herpes simplex virus vector retargeting
WO2024182737A1 (en) * 2023-03-01 2024-09-06 The Brigham And Women’S Hospital, Inc. Oncolytic viruses to treat brain cancer
CN117085049A (zh) * 2023-08-18 2023-11-21 复旦大学附属中山医院 溶瘤单疱病毒oHSV联合BET抑制剂JQ1在治疗恶性胶质瘤中的应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244792A (en) 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
JPH0668B2 (ja) 1985-08-30 1994-01-05 財団法人化学及血清療法研究所 単純ヘルペスウイルス遺伝子が組込まれた組換えプラスミド
US5849572A (en) 1990-10-10 1998-12-15 Regents Of The University Of Michigan HSV-1 vector containing a lat promoter
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5879934A (en) 1992-07-31 1999-03-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
GB9415369D0 (en) 1994-07-29 1994-09-21 Lynxvale Ltd Mutant virus
US6261552B1 (en) 1997-05-22 2001-07-17 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus vectors
GB9700411D0 (en) 1997-01-10 1997-02-26 Univ London Eukaryotic gene expression cassette and uses thereof
WO1999006583A1 (en) 1997-07-31 1999-02-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Targeted hsv vectors
ATE305510T1 (de) 1997-12-17 2005-10-15 Immunex Corp Zelloberflächenglycoproteinen zusammenhang mit menschlicher b zell lymphomen - ulbp, dns und polypeptiden
EP1002864A1 (en) 1998-11-10 2000-05-24 Universita' degli studi di Bologna HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections
US6897057B1 (en) * 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
GB9930418D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
EP1381280B1 (en) * 2001-03-27 2011-05-11 Catherex, Inc. Viral vectors and their use in therapeutic methods
MXPA04003057A (es) 2001-10-04 2005-06-20 Immunex Corp Proteina 4 de enlace ul16.
KR100900249B1 (ko) 2001-12-07 2009-05-29 포항공과대학교 산학협력단 ＳＩＶｍａｃ239의 면역원성 플라스미드 및 이들을 함유한ＡＩＤＳ ＤＮＡ 백신
US20050255085A1 (en) 2002-03-01 2005-11-17 Yuman Fong Prevention of recurrence and metastasis of cancer
US8927251B2 (en) 2002-10-07 2015-01-06 The University Of Chicago Targeting of herpes simplex virus to specific receptors
US7473418B2 (en) * 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
EP1805213B1 (en) 2004-10-28 2015-11-18 University of Pittsburgh - Of the Commonwealth System of Higher Education Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
SI2002003T1 (sl) 2005-05-27 2016-05-31 Ospedale San Raffaele S.R.L. Genski vektor, ki vsebuje mi-RNA
US20080008686A1 (en) 2006-07-10 2008-01-10 The Brigham And Women's Hospital, Inc. Tetracycline repressor regulated oncolytic viruses
US8586028B2 (en) 2007-05-09 2013-11-19 Board Of Supervisors Of Lousiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses type-1 for treatment of cancers
WO2008143875A1 (en) 2007-05-14 2008-11-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
WO2009111892A1 (en) * 2008-03-14 2009-09-17 Ottawa Health Research Institute Microrna mediated oncolytic targeting
EP2307033A4 (en) 2008-05-29 2012-06-13 Gen Hospital Corp USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS
NO2700405T3 (es) 2008-05-29 2018-09-01
GB0810912D0 (en) 2008-06-13 2008-07-23 Inst Animal Health Ltd Vector
CA2755245A1 (en) 2009-03-13 2010-09-16 Egen, Inc. Compositions and methods for the delivery of biologically active rnas
CA2795695A1 (en) 2010-04-09 2011-10-13 The University Of Tokyo Microrna-controlled recombinant vaccinia virus and use thereof
WO2011130749A2 (en) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
WO2012006181A2 (en) 2010-06-29 2012-01-12 Mount Sinai School Of Medicine Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
US20130156808A1 (en) 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
KR102382295B1 (ko) 2013-07-17 2022-04-04 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 효율적인 유전자 전달 적용을 위한 비독성 hsv 벡터 및 이의 생산을 위한 보완 세포
JP6588024B2 (ja) 2013-10-28 2019-10-09 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 腫瘍溶解性ｈｓｖベクター

Also Published As

Publication number Publication date
EP3184641B1 (en) 2020-07-08
KR102330183B1 (ko) 2021-11-23
CA2928956A1 (en) 2015-05-07
EP3063279B1 (en) 2020-01-01
HK1225756A1 (en) 2017-09-15
US10188686B2 (en) 2019-01-29
RU2016120618A3 (es) 2018-05-22
JP6919912B2 (ja) 2021-08-18
CN106068326B (zh) 2021-06-18
PT3184641T (pt) 2020-08-21
JP2020058341A (ja) 2020-04-16
JP7262134B2 (ja) 2023-04-21
EP3063279A1 (en) 2016-09-07
US20190262410A1 (en) 2019-08-29
AU2014342465B2 (en) 2018-03-08
US20170274025A1 (en) 2017-09-28
ES2781852T3 (es) 2020-09-08
US20210138007A1 (en) 2021-05-13
DK3184641T3 (da) 2020-08-03
JP2016537020A (ja) 2016-12-01
IL245312B (en) 2020-02-27
EP3778906A1 (en) 2021-02-17
IL245312A0 (en) 2016-06-30
NZ720021A (en) 2022-08-26
RU2016120618A (ru) 2017-12-06
US10201575B2 (en) 2019-02-12
RU2719190C2 (ru) 2020-04-17
ES2810800T3 (es) 2021-03-09
IL272480B (en) 2021-06-30
JP6588024B2 (ja) 2019-10-09
JP2021180661A (ja) 2021-11-25
BR112016009465A8 (pt) 2018-01-30
MX2016005488A (es) 2016-10-03
US20170035819A1 (en) 2017-02-09
EP3063279A4 (en) 2017-05-17
AU2014342465A1 (en) 2016-06-02
BR112016009465A2 (pt) 2017-10-03
MX2021001158A (es) 2021-04-28
IL272480A (en) 2020-03-31
SG11201603119RA (en) 2016-05-30
US11883448B2 (en) 2024-01-30
EP3184641A1 (en) 2017-06-28
CN106068326A (zh) 2016-11-02
KR20160108301A (ko) 2016-09-19
KR102490462B1 (ko) 2023-01-19
CN113717952A (zh) 2021-11-30
WO2015066042A1 (en) 2015-05-07
US20160250267A1 (en) 2016-09-01
US10172893B2 (en) 2019-01-08
KR20210145296A (ko) 2021-12-01
EP3778906B1 (en) 2025-07-02
US10576115B2 (en) 2020-03-03

Similar Documents

Publication Publication Date Title
MX2021001158A (es) Vector hsv oncolitico.
Moloney et al. ROS signalling in the biology of cancer
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
SG10201901482XA (en) Oncolytic adenovirus encoding a b7 protein
MX2024007924A (es) Edicion genomica multiplexada.
CY1121591T1 (el) Ογκολυτικος ιος απλου ερπητα και θεραπευτικες χρησεις αυτου
MX2018001617A (es) Composiciones de crispr-cas9 diseñados y metodos de uso.
WO2016106404A3 (en) Methods and compositions for treating malignant tumors associated with kras mutation
EP4434997A3 (en) Delivery of negatively charged proteins using cationic lipids
HK1246180A1 (zh) 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法
CR20170282A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer
CR20250153A (es) RECEPTORES DE CÉLULAS T QUE RECONOCEN P53 MUTADO (Divisional Expediente 2020-0170)
AU2016262093A8 (en) Enhancing endonuclease based gene editing in primary cells
WO2016073955A3 (en) Cells lacking b2m surface expression and methods for allogeneic administration of such cells
EA201690529A1 (ru) Способы модификации клетки-хозяина
MX2021015877A (es) Receptores de celulas t que reconocen la mutacion r175h o y220c en p53.
WO2018104909A3 (en) Dna methylation profiling for t-cell immunotherapy
EP4599893A3 (en) Cg0070 for treating bcg resistant bladder carcinoma in situ
WO2017053629A3 (en) Light-controlled gene delivery with virus vectors through incorporation of optogenetic proteins and genetic insertion of non-conformationally constrained peptides
WO2020065404A3 (en) Methods and compositions for selection of functional aptamers
MX2021005980A (es) Adenovirus y metodos para usar adenovirus.
MX2023002591A (es) Interfaces de proteina.
PH12017500109A1 (en) Composition for treating cancerous cells and a method therefor
MX2020004530A (es) Producto y proceso para emplear conjugados de union a antigeno basados en gc7 (n1-guanil-1,7-diaminoheptano) en terapia de cancer.
CO6571869A2 (es) Péptidos ect2 y vacunas que los incluyen